B群脑膜炎球菌疫苗(辉瑞): 一种免疫刺激剂药物,由Pfizer Inc. (Pfizer Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: 免疫刺激剂,治疗领域: 感染,在研适应症: 脑膜炎球菌感染,在研机构: Pfizer Europe MA EEIG,Wyeth Pharmaceuticals LLC,PF Con
The virus that causes measles, for instance, is a very stable virus, it doesn't change -basically, the virus today is the same as it was in 1935, Flu and COVID viruses, on the other hand, change frequently, so the vaccine s need to be updated and repeated.(虽然有些疫苗在儿童时期...
2014. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol 14:111. http://dx.doi .org/10.1186/1471-2180-14-111.Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, et al. (2014) Diversity of greek ...
The CDC-recommended age for MenB vaccination is 16 to 23 years (preferred age 16 to 18 years).9,10 You can help protect your teen by vaccinating with TRUMENBA, which is FDA approved for MenB.1 Routine visits with your child's doctor are a good opportunity to discuss the risks and ...
Background In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure on the basis of special consideration by the Food and Drug Administration to respond to an outbreak of Neisseria meningitidis B at a U.S. university. Data suggested that vaccination ...
Summary A century of traditional vaccinology lost the fight against meningococcus serogroup B (MenB). However, thanks to an innovative genome-based approach, the first broadly effective MenB vaccine, Bexsero® (GSK Vaccines), was developed and has b
Porin A (PorA), which determines the serosubtype of Neisseria meningitidis, is the main antigen of a candidate vaccine against serogroup B meningococci,which has been shown to induce high-avidity antibodies in children. We characterized the immune response of children after convalescing from mening...
A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents ...
Porin A (PorA), which determines the serosubtype of Neisseria meningitidis, is the main antigen of a candidate vaccine against serogroup B meningococci, which has been shown to induce high-avidity antibodies in children. We characterized the immune response of children after convalescing from meni...
Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero<sup class="a-plus-plus">®</sup>) is a unique vaccine containing four main immunogenic components: three recombinant proteins combined with outer membrane vesicles derived from meningococcal NZ98/254 strain. After three doses of 4...